AngioDynamics, Inc. (ANGO) EPS Estimated At $0.21

June 14, 2018 - By Christine McCrea

AngioDynamics, Inc. (NASDAQ:ANGO) LogoInvestors sentiment increased to 1.46 in 2018 Q1. Its up 0.20, from 1.26 in 2017Q4. It is positive, as 17 investors sold AngioDynamics, Inc. shares while 40 reduced holdings. 25 funds opened positions while 58 raised stakes. 34.89 million shares or 2.93% more from 33.90 million shares in 2017Q4 were reported.
Chicago Equity Partners Limited Liability Company has 40,825 shares. Sterling Capital Mngmt Limited Liability Company invested in 0.01% or 37,524 shares. Laurion Management Ltd Partnership invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO). 182,312 are held by Nordea Investment Management. Deutsche Commercial Bank Ag reported 0% stake. Swiss Bancorporation holds 0% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO) for 61,000 shares. Parkside Finance National Bank And holds 0% or 37 shares in its portfolio. The Illinois-based Ubs Asset Americas has invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Spark Investment Management Ltd Liability has invested 0.1% in AngioDynamics, Inc. (NASDAQ:ANGO). Wellington Management Group Inc Llp holds 0% or 11,650 shares in its portfolio. Bailard Inc has 0.02% invested in AngioDynamics, Inc. (NASDAQ:ANGO) for 16,100 shares. Thrivent Fincl For Lutherans accumulated 23,723 shares or 0% of the stock. Bridgeway Management holds 207,600 shares or 0.04% of its portfolio. Tiaa Cref Management Limited Company accumulated 196,593 shares. Public Employees Retirement Association Of Colorado owns 16,356 shares or 0% of their US portfolio.

Analysts expect AngioDynamics, Inc. (NASDAQ:ANGO) to report $0.21 EPS on July, 17.They anticipate $0.02 EPS change or 10.53 % from last quarter’s $0.19 EPS. ANGO’s profit would be $7.73M giving it 25.75 P/E if the $0.21 EPS is correct. After having $0.25 EPS previously, AngioDynamics, Inc.’s analysts see -16.00 % EPS growth. The stock increased 0.79% or $0.17 during the last trading session, reaching $21.63. About 106,900 shares traded. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 30.75% since June 14, 2017 and is uptrending. It has outperformed by 18.18% the S&P500.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

Among 3 analysts covering Angiodynamics (NASDAQ:ANGO), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Angiodynamics had 5 analyst reports since January 5, 2018 according to SRatingsIntel. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) earned “Hold” rating by Canaccord Genuity on Monday, April 2. Craig Hallum downgraded AngioDynamics, Inc. (NASDAQ:ANGO) on Friday, January 5 to “Hold” rating. The firm earned “Outperform” rating on Tuesday, April 3 by Raymond James. The company was maintained on Thursday, January 4 by Canaccord Genuity. The stock has “Hold” rating by Canaccord Genuity on Thursday, March 29.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company has market cap of $796.08 million. The firm provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It has a 600.83 P/E ratio. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

More news for AngioDynamics, Inc. (NASDAQ:ANGO) were recently published by: Nasdaq.com, which released: “Research Report Identifies AngioDynamics, Kaiser Aluminum, Mammoth Energy Services, Meridian Bioscience …” on May 29, 2018. Benzinga.com‘s article titled: “Benzinga’s Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time” and published on June 01, 2018 is yet another important article.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: